Pfizer Update

The leading COVID vaccine is in phase 2/3 in its trials.

They have clinical trial sites in 39 US states enrolling participants 12 and over, almost 40,000 participants are in the study for vaccination in the trials.

30% of its participants have diverse backgrounds, with it being 43% outside of the United States.

Proceeding on with the upcoming trials, they can see phase 3 coming very quickly, along with 100 million doses by the end of 2020 if approved, and by 2021 there could be about 1.3 billion doses if the vaccine is available.

source: https://www.pfizer.com/science/coronavirus/vaccine